NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research”

SOLCITATION H27-1001 Description of Work: Frederick National Laboratory for Cancer Research (FNLCR) Operated by Leidos Biomedical Research, Inc. (Leidos Biomed) for the National Cancer Institute requires an Indefinite Delivery/Indefinite Quantity Subcontract for construction services for the Frederick National Laboratory for Cancer Research (FNLCR). To obtain a copy of solicitation H27-1001 and other information concerning this opportunity, please refer to: https://frederick.cancer.gov/work-us/vendors-subcontractors/business-opportunities/construction-idiq-contract or contact Matthew Hull (Contracts Manager) at matthew.hull@nih.gov For information concerning other opportunities with the FNLCR, please refer to: https://frederick.cancer.gov/workwithus/solicitations Background Information: Leidos Biomedical Research, Inc. (Leidos Biomed), a subsidiary of Leidos Corporation, a Delaware corporation with offices in Frederick, MD is the Operations and Technical Support (OTS) contractor for the National Cancer Institute at Frederick. The effort to be performed will be part of Leidos Biomed’s Prime Contract 75N91019D00024 that has been issued by the National Cancer Institute, National Institutes of Health, Frederick, MD. The FNLCR is a Government-Owned Contractor-Operated Federally Funded Research and Development Center (FFRDC) located at Fort Detrick, Maryland. The FNLCR partners with university, Government, and corporate scientists to speed the translation of laboratory research into new diagnostic tests and treatments for cancer and AIDS. FNLCR is a multi-program laboratory currently operated by Leidos Biomedical Research, Inc. (Leidos Biomed) for the National Cancer Institute (NCI) under Prime Contract No. 75N91019D00024 & HHSN261201500003I, which provides Operations and Technical Support (OTS) for the FNLCR. The Government assumes no liability for reimbursement for any effort or associated costs to respond, nor for any information provided as a result of this Special No